Tag: Follicular lymphoma
Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials
Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the 2023 American Society of Hematology (ASH) Annual ... Read More
Genentech bags Lunsumio FDA approval for R/R follicular lymphoma
Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US Food and Drug Administration (FDA) for Lunsumio ... Read More
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More
Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma
Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). ... Read More
Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma
Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular ... Read More
Nordic Nanovector initiates Betalutin rituximab combo trial in 2L FL
Nordic Nanovector has announced the dosing of the first patient in a phase 1b clinical trial called Archer-1 for evaluating the combination of its investigational ... Read More
Nordic Nanovector initiates mid-stage trial of Betalutin in 3L Follicular Lymphoma in US
Nordic Nanovector has opened its first clinical site in the US at Long Beach in California for the PARADIGME trial to evaluate its tumor-seeking anti-CD37 ... Read More